Avalanche and Lonza partner to manufacture high volumes of viral vectors
This article was originally published in Scrip
Avalanche Biotechnologies in San Francisco and biologics manufacturer Lonza entered into a collaboration to produce adeno-associated viral (AAV) vectors for gene therapy at a scale that supports late stage development for Avalanche's age-related macular degeneration (AMD) therapy AVA-101 and for third-party companies.
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.